Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53

被引:0
|
作者
W Troy Loging
David Reisman
机构
[1] University of South Carolina,Department of Biological Sciences
来源
Oncogene | 1999年 / 18卷
关键词
mutant p53; gene expression; TIMP-3; tumor suppressor;
D O I
暂无
中图分类号
学科分类号
摘要
The p53 gene is a tumor suppressor that regulates the expression of genes required for cell cycle arrest or apoptosis. Mutations in p53 have been observed in over 60% of all human cancers. Certain classes of mutant p53 proteins maintain some of their activities or acquire novel activities and thus may contribute to the transformed phenotype. By carrying out an analysis of differential gene expression using cDNA expression arrays, we compared the expression patterns of cells expressing no p53 to isogenic lines expressing the codon 248 Arg to Trp mutant p53 allele (R248W). In this report, we show that the R248W and D281G p53 mutants, two of the more commonly occurring mutations, as well as wild type p53, repress transcription of the tissue inhibitor of metalloproteinases type 3 (TIMP-3) gene by greater than tenfold. TIMP-3 expression has been observed to be repressed in many tumors and its reduced expression is thought to contribute to tumor metastasis and invasiveness by allowing increased activity of metalloproteinases in the extracellular matrix. Since mutant forms of p53 tend to be expressed at greatly elevated levels in many human tumors, the retention of their ability to repress TIMP-3 illustrate one mechanism by which mutant forms of the p53 gene may contribute to tumorigenesis.
引用
收藏
页码:7608 / 7615
页数:7
相关论文
共 50 条
  • [41] Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide
    Bernal, Federico
    Tyler, Andrew F.
    Korsmeyer, Stanley J.
    Walensky, Loren D.
    Verdine, Gregory L.
    Journal of the American Chemical Society, 2007, 129 (09): : 2456 - 2457
  • [42] Construction of chimeric tumor suppressor p53 resistant to the dominant-negative interaction with p53 mutants
    Almazov, VP
    Morgunkova, AA
    Kalinin, VN
    Kopnin, BP
    Prasolov, VS
    Chumakov, PM
    MOLECULAR BIOLOGY, 2002, 36 (04) : 522 - 527
  • [43] Construction of Chimeric Tumor Suppressor p53 Resistant to the Dominant-Negative Interaction with p53 Mutants
    V. P. Almazov
    A. A. Morgunkova
    V. N. Kalinin
    B. P. Kopnin
    V. S. Prasolov
    P. M. Chumakov
    Molecular Biology, 2002, 36 : 522 - 527
  • [44] Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins
    Moos, PJ
    Edes, K
    Fitzpatrick, FA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (16) : 9215 - 9220
  • [45] THE P53 TUMOR-SUPPRESSOR GENE AND TUMOR PROGNOSIS - IS THERE A RELATIONSHIP
    DOWELL, SP
    HALL, PA
    JOURNAL OF PATHOLOGY, 1995, 177 (03): : 221 - 224
  • [46] DIFFERENT TUMOR-DERIVED P53 MUTANTS EXHIBIT DISTINCT BIOLOGICAL-ACTIVITIES
    HALEVY, O
    MICHALOVITZ, D
    OREN, M
    SCIENCE, 1990, 250 (4977) : 113 - 116
  • [47] Tumor-derived p53 mutants induce NF-κB2 gene expression
    Scian, MJ
    Stagliano, KER
    Anderson, MAE
    Hassan, S
    Bowman, M
    Miles, MF
    Deb, SP
    Deb, S
    MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (22) : 10097 - 10110
  • [48] Effect of prothymosin α and its mutants on the activity of the p53 tumor suppressor
    N. I. Zakharova
    V. V. Sokolov
    V. V. Roudko
    S. V. Melnikov
    A. B. Vartapetian
    A. G. Evstafieva
    Molecular Biology, 2008, 42 : 598 - 608
  • [49] Effect of prothymosin α and its mutants on the activity of the p53 tumor suppressor
    Zakharova, N. I.
    Sokolov, V. V.
    Roudko, V. V.
    Melnikov, S. V.
    Vartapetian, A. B.
    Evstafieva, A. G.
    MOLECULAR BIOLOGY, 2008, 42 (04) : 598 - 608
  • [50] Physical interaction with human tumor-derived p53 mutants inhibits p63 activities
    Strano, S
    Fontemaggi, G
    Costanzo, A
    Rizzo, MG
    Monti, O
    Baccarini, A
    Del Sal, G
    Levrero, M
    Sacchi, A
    Oren, M
    Blandino, G
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (21) : 18817 - 18826